$KTOV DD Thread:

I will never lie to my followers or lead you astray on purpose.

Let’s get started.

Consensi IS NOT the main catalyst for KTOV

CM-24 IS NOT the main catalyst for KTOV.

NT-219 (IS) the main catalyst.

First I want to answer a question a follower asked about earlier.

“I read an article that says that @Merck already owns @Kitov_Pharma drug CM-24 and the same investors are mentioned. That all changed when FamWave was acquired by Kitov.”

As part of the recently announced agreement for the acquisition of FameWave by Kitov, cCAM BioTherapeutics Ltd., a wholly owned subsidiary of Merck Sharp and Dohme Corp., known as “MSD” in Israel, has returned the rights to CM-24 to former cCAM shareholders and founders of....

FameWave, following an initial Phase 1 dose ranging study of CM-24 as single agent." https://www.globenewswire.com/news-release/2019/04/12/1803374/0/en/Kitov-Announces-Key-Milestone-in-FameWave-Acquisition.html

Why is CM-24 not the main catalyst and why do i not expect much from it?

In 2015 Merck failed with Cm-24 because of a dosage miss. So don’t get your hopes up Friday! Do I think it could go up in price, of course, but I’m not certain that dosage will fix the drug.

Now for what we’re waiting for NT-219....

First off, A COLLAB Is COMING 100% .

So, when will we see a collab for NT-219?

Guessing between now and the June 22 presentation, they'll reveal the collab partner.

Who do I think the collab partner is, either “Lilly” or “Merck” I’m leaning towards Merck, for certain reason I’ll discuss.

Also go look at $SURF. Look what happened when they announced a collab with Merck.

Merck might have their eye on nt-219, not only for Erbitux but Keytruda with which 219 was also preclinically tested with "outstanding" results. but I'm curious again to see who are the big pharma who owns those other drugs tested preclinically with nt-219....

some of those big pharma may also be interested in nt-219 based on outstanding results with all of them. Imagine these big pharmas will all be very interested to see the results of the P1/2 with Erbitux.

Now let’s check out NT-219 mice trials

Of particular interest was a model, which originated from a biopsy of R/M HNSCC patient previously treated and progressed on radiation, various chemotherapies, and pembrolizumab, where autologous PBMC’s were injected. Administration of NT219 as a monotherapy resulted in tumor...

growth inhibition (TGI) of 69% (p-value=0.017). In combination with cetuximab, NT219 induced regression of all tumors. While cetuximab alone demonstrated modest TGI (17%), the addition of NT219 showed synergistic effect and complete TGI (p-value=0.001)."

If their human trials are any where as good as their mice trials, then monumental will be the word for this stock.

So I repeat, NT-219 will be what makes KTOV.

We will see a substantial increase in SP once they announce their collab. Mark my words.

Thank you for your time!